IGM Biosciences stock has experienced a significant decline, indicating an overall bearish sentiment in the market. The company's high expenses and poor financial management have devalued the company.

CNW/ - ("IGM" or "the Company") (TSX: IGM), one of Canada's leading diversified wealth and asset management companies, today ...

IGM Financial Inc. (IGM) (TSX: IGM) today reported total assets under management and advisement reached an all-time record high of $307.1 billion at October 31, 2025, up 16.0% from $264.8 billion at ...

IGM Financial’s fair value estimate has recently risen from CA$54.43 to CA$56.71. This increase reflects growing optimism among equity analysts, driven by expectations for improved growth and ongoing ...

IGM Biosciences, Inc. is halting the development of its bispecific antibodies imvotamab and IGM-2644 due to insufficient data from clinical trials, specifically regarding B cell depletion for treating ...

4 analysts have expressed a variety of opinions on IGM Biosciences (NASDAQ:IGMS) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

Higher interest rates and worries about banking system stability and a recession have rocked the market and caused the energy and financial Sectors to sell off. Surprisingly enough to some investors, ...

Researchers at UMC Utrecht have discovered that converting monoclonal antibodies from the IgG to the IgM isotype can significantly broaden their ability to recognize and bind multiple human-relevant ...

IGM's combination of the in-house investment management groups from Mackenzie and Investors Group into a single shop (housed under the Mackenzie Investments brand) has enhanced the scale of the firm's ...

In the last three months, 5 analysts have published ratings on IGM Biosciences (NASDAQ:IGMS), offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of ...